Osteosarcoma Clinical Trials
Here are the 6 most popular medical studies for osteosarcoma
CAR T-cell Therapy
CAR T-Cells for Neuroblastoma
This trial is testing a new cancer treatment that combines two existing ways of fighting disease: antibodies and T cells. Antibodies are molecules that fight infections and protect your body from diseases caused by bacteria and toxic substances. T cells are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected. The new treatment being researched is called autologous T lymphocyte chimeric antigen receptor cells (CAR) cells targeted against the disialoganglioside (GD2) antigen that express Interleukin (IL)-15, and the inducible caspase 9 safety switch (iC9
Angiotensin II Receptor Blocker
Losartan + Sunitinib for Osteosarcoma
This trial is testing a combination of two drugs to see what the highest dose is that people can tolerate without serious side effects. Once they find that, they'll test that dose to see if it's effective.
Popular filter options for osteosarcoma trials
Rhabdomyosarcoma Clinical Trials
View 38 Rhabdomyosarcoma medical studies.
Checkpoint Inhibitor
Dual Checkpoint Inhibition + Cryoablation for Pediatric Solid Tumors
“ We are looking for Clinical trial, Priyakshi already undergone VAC & VDC followed by Pazopanib and Everlomus. Currently under medication for TRAMETINIB.”
CAR T-cell Therapy
B7-H3 CAR T-cell Therapy for Pediatric Patients with Solid Tumors
This trial is for patients ≤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
Radioisotope
CLR 131 for Malignant Tumors
This trial is testing a new cancer treatment called CLR 131 in children, adolescents, and young adults with cancer that has come back or didn't respond to initial treatment and for which there are no standard treatment options.
Ewing Sarcoma Clinical Trials
View 33 Ewing Sarcoma medical studies.
Checkpoint Inhibitor
Dual Checkpoint Inhibition + Cryoablation for Pediatric Solid Tumors
“ We are looking for Clinical trial, Priyakshi already undergone VAC & VDC followed by Pazopanib and Everlomus. Currently under medication for TRAMETINIB.”
CAR T-cell Therapy
B7-H3 CAR T-cell Therapy for Pediatric Patients with Solid Tumors
This trial is for patients ≤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
Metastatic Osteosarcoma Clinical Trials
View 74 metastatic osteosarcoma medical studies.
Virus Therapy
KB707 for Solid Tumors
This trial tests a new drug (KB707) to see if it's safe & effective for adults with cancer that has progressed or they can't tolerate current treatments. Patients get the drug directly injected into tumors.
Procedure
Thoracotomy versus Thoracoscopic Management for Osteosarcoma
“ I want to help my husband who has been diagnosed with oscrsarcoma it has spread to his lymph nodes and reqlly want information om anything to help him please many thanks tina biles x.”
Immunotherapy
Haploidentical Transplantation + Zoledronate for Pediatric Hematologic Malignancies and Solid Tumors
This trial is testing a new way to transplant stem cells from a donor who is only a half-match to the patient, using a drug to remove TCRαβ+ cells and CD19+ cells.
Chemotherapy
Doxorubicin for Sarcoma
This trial is testing a new technique for delivering chemotherapy directly into the lungs at the time of surgery. The goal is to kill any microscopic cancer cells that are present in the lungs at the time of surgery, while sparing other major organs in the body from the side effects of chemotherapy.
Osteosarcoma Clinical Trials With No Placebo
View 74 osteosarcoma medical studies that do not have a placebo group.
Virus Therapy
KB707 for Solid Tumors
This trial tests a new drug (KB707) to see if it's safe & effective for adults with cancer that has progressed or they can't tolerate current treatments. Patients get the drug directly injected into tumors.
Checkpoint Inhibitor
Dual Checkpoint Inhibition + Cryoablation for Pediatric Solid Tumors
“ We are looking for Clinical trial, Priyakshi already undergone VAC & VDC followed by Pazopanib and Everlomus. Currently under medication for TRAMETINIB.”
Procedure
Thoracotomy versus Thoracoscopic Management for Osteosarcoma
“ I want to help my husband who has been diagnosed with oscrsarcoma it has spread to his lymph nodes and reqlly want information om anything to help him please many thanks tina biles x.”
CAR T-cell Therapy
B7-H3 CAR T-cell Therapy for Pediatric Patients with Solid Tumors
This trial is for patients ≤ 21 years old with relapsed/refractory B7-H3+ solid tumors, investigating the use of autologous T cells genetically engineered to express B7-H3-CARs. The study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.
View More Osteosarcoma Trials
See another 51 many medical studies focused on osteosarcoma.
Frequently Asked Questions
Introduction to osteosarcoma
What are the top hospitals conducting osteosarcoma research?
When it comes to advancing the treatment of osteosarcoma, Children's hospitals across the United States are leading the charge. In Aurora, Colorado, Children's Hospital Colorado is at the forefront with an impressive 23 active clinical trials focused on this bone cancer. Since their first recorded osteosarcoma trial in 2005, they have conducted a total of 34 studies dedicated to improving outcomes for young patients facing this challenging disease.
Meanwhile, in Los Angeles, California, Children's Hospital Los Angeles is also making significant strides in osteosarcoma research. With 22 ongoing trials and a total of 43 completed studies since their pioneering osteosarcoma trial in 1999, this institution has been committed to finding innovative approaches to tackle this aggressive form of cancer.
On the other side of the country in Washington D.C., Children's National Medical Center is actively involved in pushing boundaries against osteosarcoma as well. They currently have 22 ongoing clinical trials and have completed a commendable number of 40 investigations since recording their first study on this condition back in 1999.
In Birmingham, Alabama, children battling osteosarcoma can find hope at the Children's Hospital of Alabama. This hospital boasts an impressive lineup with its involvement in twenty active clinical trials and thirty-five previous projects devoted solely to tackling this challenging cancer subtype since starting their inaugural study on it backin2005.
Lastly but not least important Riley Hospital for Children located Indianapolis has also emerged as a key player with twenty current ongoing tests aided by35 previously held experiments exclusively targetingOsteocarcinoma ; And all these initiated from year2005 marking foundation stones laid towards discovery through various exploration strategies
These esteemed institutions represent beacons of hope for those affected by osteosarcoma and serve as prime examples that collaboration among top pediatric hospitals can lead us closer towards breakthroughs that will transform lives around the world
Which are the best cities for osteosarcoma clinical trials?
In the realm of osteosarcoma clinical trials, several cities emerge as top contenders. New York City leads the way with 65 active trials exploring various treatments like Pharmacological Study, Tazemetostat, and Tipifarnib. Saint Louis, Missouri follows closely behind with 52 ongoing studies investigating interventions such as Pharmacological Study, Vemurafenib, and Dinutuximab. Houston, Texas is another notable hub for research with 49 active trials examining methodologies like Thoracoscopy and MM-398 plus cyclophosphamide. Lastly, Los Angeles, California. New York City leads the way with 65 active trials exploring various treatments like Pharmacological Study, Tazemetostat, and Tipifarnib. Saint Louis, Missouri follows closely behind with 52 ongoing studies investigating interventions such as Pharmacological Study, Vemurafenib, and Dinutuximab. Houston, Texas is another notable hub for research with 49 active trials examining methodologies like Thoracoscopy and MM-398 plus cyclophosphamide. Lastly, Los Angeles, California and Orlando, Florida both exhibit significant activity in osteosarcoma trials with a focus on Pharmalogical Study alongside different therapeutic options including Doxorubicin and Olaparib. These cities provide opportunities to participate in cutting-edge clinical trials that are crucial in advancing our knowledge and treatment approaches towards osteosarcoma.
Which are the top treatments for osteosarcoma being explored in clinical trials?
Osteosarcoma, a challenging bone cancer, is the focus of several cutting-edge treatments currently being explored in clinical trials. Among them are:
- Pharmacological Study: With three active trials and 13 all-time osteosarcoma trials since its introduction in 2010, this treatment option shows promise.
- Nivolumab: Introduced in 2015, nivolumab has shown potential with two active trials and seven all-time osteosarcoma trials to date.
- Abemaciclib: First listed in 2016, abemaciclib is involved in two ongoing clinical trials for osteosarcoma.
- Doxorubicin: A veteran on the scene since 2003, doxorubicin continues to be studied with two active and seven all-time osteosarcoma trials under its belt.
- UB_TT170: Although relatively new (listed only in 2022), UB_TT170 already boasts one active trial dedicated to exploring its potential as an effective treatment for osteosarcoma. As research progresses further, these innovative treatments offer hope for improved outcomes among patients battling this relentless disease.
What are the most recent clinical trials for osteosarcoma?
Recent clinical trials for osteosarcoma offer hope and potential breakthroughs in the treatment of this aggressive bone cancer. Part A of a Phase 1 trial focuses on determining the maximum tolerated dose (MTD) for osteosarcoma, paving the way for more targeted therapies. Another Phase 1 trial explores NPX267 as a potential treatment option, while Cabozantinib undergoes evaluation in a Phase 2 study. Additionally, combination treatments involving chemotherapy and NK cell infusion are being investigated through both Phase 1 and Phase 2 trials. These studies represent significant advancements in our understanding of osteosarcoma therapy and bring us closer to improved outcomes for patients facing this challenging disease.
What osteosarcoma clinical trials were recently completed?
Recent advancements in clinical trials for osteosarcoma offer hope and progress towards improved treatments. In December 2020, the Dana-Farber Cancer Institute completed a trial investigating the potential of Cabozantinib to address this aggressive bone cancer. Additionally, in May 2018, Washington University School of Medicine concluded their study on pegylated arginine deiminase as a potential therapeutic option. Furthermore, St. Jude Children's Research Hospital successfully completed a trial testing Avelumab in February 2017. These recent developments highlight the ongoing efforts to combat osteosarcoma and provide renewed optimism for patients fighting against this devastating disease.